

Q2 2024 MarketScan Spotlight

Spotlight of the Quarter: MarketScan Mortality Database



MarketScan Mortality Database launched!

In January 2024, we proudly launched the MarketScan® Mortality Database. Through a data license, researchers can now access mortality data sourced from:

- MarketScan data contributors, capturing inpatient deaths
- Social Security Administration (SSA) Death Master File (DMF)

The MarketScan Mortality Database is a notable addition to the trusted MarketScan brand, which helps advance research to generate real-world evidence that can improve healthcare delivery outcomes and inform policy decision-making.



Why is mortality data important?

Mortality is one of the most objectively measurable endpoints in health outcomes research. With MarketScan Mortality Database, you can:

- **Evaluate** population level mortality rates and risk modeling
- **Analyze** patient survival
- **Identify** predictors of death-related outcomes



Validation analysis showed that a combination of inpatient death and the DMF effectively increased the accuracy and reliability of death ascertainment.


A validation analysis was conducted using a random sample of 6,000 individuals from the MarketScan Mortality Database. The analysis assessed sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and death date concordance were assessed against the National Death Index (NDI), considered the gold standard. These metrics were calculated separately for:

- Inpatient death
- The DMF
- The combination of these two sources which represents the MarketScan Mortality Database.


Findings indicate that deaths recorded in inpatient or the DMF were accurate and had high degree of precision on date of death.

- **Sensitivity and NPV:** were both improved when considering deaths from inpatient death and the DMF
- **Specificity and PPV:** Regardless of the source, specificity and the probability of accurately identifying death (PPV) were consistently high.
- **Date Concordance:** Inpatient death data, the DMF, and the MarketScan Mortality Database showed a high concordance rate of 98% or higher for the date of death within a 1-15 day range from the NDI.

Sensitivity, Specificity, PPV, NPV: NDI vs Inpatient Death, DMF, and MarketScan Mortality Database




Death Date Concordance: NDI vs Inpatient Death, DMF, and MarketScan Mortality Database



Getting mortality data from multiple sources boosts the ability to conduct mortality analyses.

In a 2024 ISPOR poster¹ [\[link\]](#) among patients with metastatic lung cancer or septicemia from MarketScan Mortality Database, Liu et al. reported that death from inpatient and the DMF had low overlap. Using the NDI, overall PPV was 98.6% for death reported in inpatient discharge status or the DMF, suggesting that the two data sources are complementary and accurate.

Mortality Data Overlap Analysis



Low overlapping rates of death reported from inpatient claims and the DMF

- Death recorded in either Inpatient Claims or the DMF
- Death recorded in both Inpatient Claims and the DMF



Did you know that it is possible to analyze productivity loss using MarketScan Health & Productivity Management (HPM) database?

Core Value Proposition:

To offer insights into productivity loss or societal costs associated with a disease or treatment for patients as well as their caregivers.

Potential Use Cases Include:

- Direct and Indirect (Societal) Costs of Disease/Treatment
- Caregiver Burden Analysis
- Health Economic Models

*18.6M LIVES In 1997-2022



8.0M LIVES In 2017-2022*



Key Features

- Absenteeism
- Short-Term Disability
- Long-Term Disability
- Workers' Compensation



Linked To MarketScan Claims Database

- Healthcare Encounters
- Prescription Fills
- Costs

To learn more about assessing absenteeism, disability, and workers' compensation and their associated costs using the HPM Database in your research, click [here](#).



MarketScan in action

Publications

MarketScan supported 225 peer-reviewed publications in January-June 2024 across multiple academic and clinical journals such as: JAMA, American Journal of Epidemiology, Journal of the American Academy of Dermatology, Arthritis Care and Research, etc.

Conferences

MarketScan data was extensively represented at ISPOR Global in Atlanta, Georgia in May 2024. More than 70 presentations, including 15 co-authored by our researchers, leveraged MarketScan data across various healthcare topics.

Click [here](#) to view the presentations.

Blogs

Every month, the MarketScan team pulls together a report with our latest findings and perspectives.

Click [here](#) to see prior postings.



Spotlight for next quarter

Next quarter will feature **Linked Claims + EHR by MarketScan and Veradigm** - A new offering of MarketScan with enriched data variables that provide a more complete view into patient healthcare utilization and costs with a deep dive into the clinical picture with ambulatory care data.

MarketScan is one of the largest collections of de-identified US patient claims data; the closed system data includes patient encounters spanning the full continuum of care including inpatient, outpatient, and outpatient pharmacy sites of care.

Veradigm Network of EHR solutions (VNEHR) encompasses data from a large national patient population drawn from diverse physician practices using the VNEHR, organized into a research-optimized common data model.

About MarketScan

MarketScan by Merative provides deidentified, longitudinal, patient-level closed claims and specialty data for 293M+ patients sourced directly from a diverse pool of payers. Industry-leading researchers rely on MarketScan to derive valuable insights pertaining to health economics and outcomes research, treatment patterns, and disease progression across the industry resulting in more than 3,500 peer-reviewed manuscripts.

Learn more at merative.com/real-world-evidence

About Merative

Merative is a data, analytics and technology partner for the health industry, including providers, health plans, employers, life sciences companies and governments. With trusted technology and human expertise, Merative works with clients to drive real progress. Merative helps clients orient information and insights around the people they serve to improve decision-making and performance. Merative, formerly IBM Watson Health, became a new standalone company as part of Francisco Partners in 2022.

Learn more at merative.com

Footnote

¹Liu Y et al. Evaluation of Mortality Data Sources for Use in Real-World Data Analyses. 2024 ISPOR, Atlanta, Georgia.

© Merative US L.P. 2024. All Rights Reserved.

Produced in the United States of America
June 2024

Merative and the Merative logo are trademarks of Merative US L.P. Other product and service names might be trademarks of Merative or other companies.

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on Merative's product plans and strategy as of the date of this publication, which are subject to change by Merative without notice. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from Merative, or stating or implying that any activities undertaken by you will result in any specific performance results. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

MSN-6992440550 Rev 1.0

